Rani Therapeutics Holdings RANI Income Statement (2020-2026)

NASDAQ RANI
$0.85 -0.07 (-7.19%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
19.44M19.53M21.41M24.37M24.47M0.02M25.38M25.52M25.88M0.03M26.29M26.49M29.81M0.03M33.57M39.24M47.94M0.07M180.00M187.17M
Revenue & cost
Revenue (Quarter)
1.03M0.17M1.46M1.71M1.71M
Operating items
Research & Development (Quarter)
11.96M7.42M7.59M9.53M9.10M10.39M9.71M11.09M11.22M7.61M7.59M6.12M6.17M6.81M6.57M5.50M3.22M4.91M5.16M5.02M
Selling, General & Administrative (Quarter)
15.82M5.95M6.19M6.32M7.24M7.10M6.80M7.21M6.63M5.83M6.45M6.41M5.63M5.46M5.62M5.00M4.04M5.09M4.89M5.52M
Other Operating Expenses (Quarter)
3.71M
Operating Expenses (Quarter)
27.78M13.36M13.78M15.85M16.34M17.48M16.52M18.29M17.86M13.43M14.03M12.52M11.80M15.99M12.19M10.51M7.26M10.00M10.05M10.54M
Operating Income (Quarter)
-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M-8.83M
EBIT (Quarter)
-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M-8.83M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.02M0.01M0.04M0.38M0.82M0.89M0.90M0.84M0.68M0.55M0.44M0.41M0.36M0.22M0.16M0.07M0.38M0.41M0.41M
Other Non Operating Income (Quarter)
-0.70M1.40M
Net income details
EBT (Quarter)
-28.66M-13.35M-13.77M-15.81M-16.32M-17.38M-16.83M-18.66M-18.33M-14.05M-14.78M-13.46M-18.05M-12.17M-12.74M-11.30M-11.96M-8.63M-10.35M-12.46M
Tax Provisions (Quarter)
0.04M-0.04M0.06M0.15M-0.11M-0.01M
Profit After Tax (Quarter)
-28.70M-13.30M-13.83M-15.97M-16.21M-41.54M-16.83M-18.66M-9.20M19.86M-14.78M-13.36M-6.78M-15.72M-12.74M-11.22M-5.41M-21.58M-7.03M-8.42M
Income from Non-Controlling Interests (Quarter)
-25.56M-8.12M-7.61M-8.34M-8.25M-8.56M-8.46M-9.36M-9.13M-6.96M-7.30M-6.56M-5.94M-6.78M-5.47M-4.53M-2.50M1.23M-0.98M-1.03M
Income from Continuing Operations (Quarter)
-28.70M-13.30M-13.83M-15.97M-16.21M-17.37M-16.83M-18.66M-18.33M-14.05M-14.78M-13.46M-18.05M-12.17M-12.74M-11.30M-11.96M-8.63M-10.35M-12.46M
Consolidated Net Income (Quarter)
-28.70M-13.30M-13.83M-15.97M-16.21M-17.37M-16.83M-18.66M-18.33M-14.05M-14.78M-13.46M-18.05M-12.17M-12.74M-11.30M-11.96M-8.63M-10.35M-12.46M
Income towards Parent Company (Quarter)
-28.70M-13.30M-13.83M-15.97M-16.21M-17.37M-16.83M-18.66M-18.33M-14.05M-14.78M-13.46M-18.05M-12.17M-12.74M-11.30M-11.96M-8.63M-10.35M-12.46M
Net Income towards Common Stockholders (Quarter)
-28.70M-13.30M-13.83M-15.97M-16.21M-17.37M-16.83M-18.66M-18.33M-14.05M-14.78M-13.46M-18.05M-12.17M-12.74M-11.30M-11.96M-8.63M-10.35M-12.46M
Additional items
EPS (Basic) (Quarter)
-1.48-0.68-0.65-0.66-0.66-729.39-0.67-0.74-0.72-551.07-0.57-0.51-0.63-427.34-0.38-0.31-0.26-130.44-0.06-0.07
EPS (Diluted) (Quarter)
-1.48-681.12-0.65-0.66-0.66-729.39-0.67-0.74-0.72-551.07-0.57-0.51-0.63-427.34-0.38-0.31-0.26-130.44-0.06-0.07
Shares Outstanding (Quarter)
19.44M19.53M21.41M24.37M24.47M0.02M25.24M25.34M25.55M0.03M26.03M26.32M28.84M0.03M33.44M36.54M46.44M0.07M180.00M187.17M
Shares Outstanding (Diluted) (Quarter)
19.44M0.02M21.41M24.37M24.47M0.02M25.24M25.34M25.55M0.03M26.03M26.32M28.84M0.03M33.44M36.54M46.44M0.07M180.00M187.17M
EBITDA (Quarter)
-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M-8.83M
Interest Expenses (Quarter)
11.40M-0.00M5.68M1.08M0.57M0.72M1.21M1.27M1.32M3.40M1.29M1.38M6.66M-2.43M0.94M0.95M4.77M0.48M2.43M4.04M
Tax Rate (Quarter)
-0.130.30-0.46-0.970.650.06